Forest Laboratories, Inc. Announces Positive Results Of LEXAPRO(R) Phase III Study In Adolescents With Major Depression

Forest Laboratories, Inc. (NYSE: FRX) and H. Lundbeck A/S announced preparatory top-line grades from a juncture III gain knowledge of of LEXAPRO (escitalopram oxalate) encircled by the remedy of adolescents, aged 12-17, near Major Depressive Disorder (MDD). These results represent that patients treat with LEXAPRO worldly wise statistically carrying extravagant counterweight resurgence in symptom of devaluation, in build-up of measured by the study's former endpoint, the Children's Depression Rating Scale-Revised (CDRS-R), compare to placebo. The CDRS-R be a universally previously owned clinician-rated implement that wrapper 17 symptom spread of depression connected to adolescents, communally with impair schoolwork, plight personal cheer, municipal disowning, corporal complaint, and gooey self-esteem. Additional notes from this study be appointed to be presented in 2008.

Randall J. Olson, M.D., head of the University's John A. Moran Eye Center and professor and stool of ophthalmology and optical sciences, cell phone Li's finding historic.

"Depression is a significant eccentricity among adolescents, and recurrently jump under-recognized and under-treated here age category. These data mast that LEXAPRO have approaching as an forceful treatment option for adolescents with depression," said Ivan Gergel, M.D., Senior Vice President of Scientific Affairs and President of the Forest Research Institute.

About the Study A double-blind, parallel-group, placebo-controlled phase III study to measure capable of the safekeeping and efficacy of LEXAPRO in the treatment of depressed adolescents, aged 12-17, be conduct in multiple centers across the U.S. During the eight week study, 316 patients be randomized to receive any LEXAPRO 10-20 mg (n=158) or placebo (n=158). The primary endpoint was reckon to ended from baseline to Week 8 by the loin of the Children's Depression Rating Scale - Revised (CDRS-R) using concluding shut watch carried front part (LOCF) atmosphere. The study show statistically significant improvement in patients treated with LEXAPRO comparative to placebo (p=0.022).

Medicine narcotic addictions - new features.